Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NASDAQ | Common Stock
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience.
Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions.
It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT.
The company was incorporated in 2013 and is headquartered in Shanghai, China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 8, 24 | -0.50 Increased by +1.96% | -0.92 Increased by +45.65% |
| Mar 11, 24 | -1.00 Decreased by -53.85% | -0.86 Decreased by -16.28% |
| Nov 7, 23 | -0.71 Increased by +57.74% | -1.04 Increased by +31.73% |
| Aug 7, 23 | -1.25 Increased by +13.19% | -0.79 Decreased by -58.23% |
| May 9, 23 | -0.51 Increased by +43.33% | -0.95 Increased by +46.32% |
| Mar 1, 23 | -0.65 Increased by +70.05% | -1.11 Increased by +41.44% |
| Nov 9, 22 | -1.68 Decreased by -66.34% | -1.25 Decreased by -34.40% |
| Aug 9, 22 | -1.44 Increased by +18.18% | -1.08 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 65.83 M Increased by +5.16% | -95.43 M Decreased by -263.61% | Decreased by -144.96% Decreased by -245.77% |
| Sep 30, 23 | 69.23 M Increased by +20.31% | -69.15 M Increased by +56.50% | Decreased by -99.89% Increased by +63.84% |
| Jun 30, 23 | 68.86 M Increased by +42.94% | -120.89 M Increased by +11.15% | Decreased by -175.56% Increased by +37.84% |
| Mar 31, 23 | 62.80 M Increased by +34.40% | -28.77 M Increased by +66.08% | Decreased by -45.81% Increased by +74.76% |
| Dec 31, 22 | 62.60 M Increased by +41.72% | -26.25 M Increased by +87.61% | Decreased by -41.92% Increased by +91.26% |
| Sep 30, 22 | 57.54 M Increased by +33.49% | -158.96 M Decreased by -64.88% | Decreased by -276.27% Decreased by -23.51% |
| Jun 30, 22 | 48.18 M Increased by +30.43% | -136.07 M Increased by +16.69% | Decreased by -282.45% Increased by +36.13% |
| Mar 31, 22 | 46.72 M Increased by +132.42% | -84.80 M Increased by +63.59% | Decreased by -181.50% Increased by +84.33% |